Literature DB >> 26811984

Ebola Virus Persistence in Semen Ex Vivo.

Robert J Fischer, Seth Judson, Kerri Miazgowicz, Trent Bushmaker, Vincent J Munster.   

Abstract

On March 20, 2015, a case of Ebola virus disease was identified in Liberia that most likely was transmitted through sexual contact. We assessed the efficiency of detecting Ebola virus in semen samples by molecular diagnostics and the stability of Ebola virus in ex vivo semen under simulated tropical conditions.

Entities:  

Keywords:  Ebola; Ebola diagnostics; Ebola virus disease; qRT-PCR; semen; sexual transmission; viruses

Mesh:

Year:  2016        PMID: 26811984      PMCID: PMC4734518          DOI: 10.3201/eid2202.151278

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


On March 20, 2015, an isolated Ebola virus disease (EVD) case was diagnosed in Liberia, 30 days after confirmation of the previous EVD case (the incubation period for Ebola virus [EBOV] infection is 4–21 days). The patient had no history of travel to areas with reported EVD, no interaction with visitors from Sierra Leone or Guinea, no funeral attendance, and no contact with a patient with EVD symptoms (). The patient, a 44-year-old woman, reportedly had unprotected sex with a male survivor of EVD (). His semen was positive for EBOV by real-time quantitative reverse transcription PCR (qRT-PCR) 199 days after symptom onset; his cycle threshold (Ct) value was 32, seven days after EBOV was confirmed in the woman (). Among the criteria for declaring an end to the Ebola outbreak in West Africa, the World Health Organization includes testing of semen of convalescent men until 2 samples are negative (). Most of these specimens will be analyzed by qRT-PCR. Therefore, during May–September 2015, we analyzed the stability of EBOV in semen by qRT-PCR and titration. Because most of the EVD diagnostic laboratories are more familiar with values obtained from blood, we compared standard curves of Ct values with the 50% tissue culture infectious dose (TCID50) per mL in semen, blood, and tissue culture medium.

The Study

Human semen and blood were obtained from Lee Biosolutions (St. Louis, MO, USA). All assays were consistent with the procedures used at the Centers for Disease Control and Prevention/National Institutes of Health laboratory at the Eternal Love Winning Africa campus in Monrovia, Liberia, to diagnose EVD in the 44-year-old woman. RNA was extracted by using a QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA, USA) following the manufacturer’s protocol, with an additional wash step of wash buffer 1. qRT-PCR was conducted by using Roche LightCycler 480 RNA Master Hydrolysis Probes (Roche, Indianapolis IN, USA) reagents with primers and probes targeting the L gene of EBOV on the SmartCycler (Cepheid, Sunnyvale, CA, USA) platform (). Ebola virus/H.sapiens-tc/GUI/2014/Makona-WPGC07 was used in all experiments. To enable comparison among the Ct values of EBOV in semen with samples routinely analyzed during the current outbreak, we constructed standard curves of EBOV in semen, blood, and medium. Matrices were spiked to 106 TCID50/mL, then serially diluted 10 times. Five biologic replicates were used to construct the curves (Figure 1, panel A). The dynamic range of the assay extends down to 10° for blood and semen. The PCR efficiency determined from the slope of the standard curve was nearly 100% for each of the matrices; the Ct value was 1.2 times higher on average for semen than for blood.
Figure 1

A) Standard curves of Ebola virus spiked into 3 matrices: semen, blood, and tissue culture medium. Samples were analyzed on the basis of 5 biologic replicates. PCR efficiency was from 98% in cell culture medium, 102% in semen, and 103% in blood. Analysis of covariance showed no significant difference (p<0.05) between the slopes of the linear regressions of blood and semen. B) Matrix dilution in which semen, blood, and tissue culture medium were 3-fold serially diluted in sterile physiologic saline solution and spiked with 104 TCID50/mL Ebola virus. The slopes for blood and medium did not differ significantly from 0. If the semen sample data are analyzed disregarding the undiluted sample, the resulting slope also does not differ significantly from 0. Ct, cycle threshold; TCID50, 50% tissue culture infectious dose. Error bars represent the mean ± SEM of 5 quantitative PCR analyses.

A) Standard curves of Ebola virus spiked into 3 matrices: semen, blood, and tissue culture medium. Samples were analyzed on the basis of 5 biologic replicates. PCR efficiency was from 98% in cell culture medium, 102% in semen, and 103% in blood. Analysis of covariance showed no significant difference (p<0.05) between the slopes of the linear regressions of blood and semen. B) Matrix dilution in which semen, blood, and tissue culture medium were 3-fold serially diluted in sterile physiologic saline solution and spiked with 104 TCID50/mL Ebola virus. The slopes for blood and medium did not differ significantly from 0. If the semen sample data are analyzed disregarding the undiluted sample, the resulting slope also does not differ significantly from 0. Ct, cycle threshold; TCID50, 50% tissue culture infectious dose. Error bars represent the mean ± SEM of 5 quantitative PCR analyses. We tested the stability of EBOV in human semen in the liquid (bulk) and dry states during an 8-day period (27°C, 80% relative humidity [RH]). EBOV was diluted in triplicate in semen to 1 × 106 and 1 × 103 TCID50/mL; 50-μL aliquots of semen were removed daily and placed into 450 μL of DMEM. Additional aliquots were obtained for qRT-PCR. To assess the stability in dried semen, 50 μL of spiked semen was spread onto the bottom of each well of a 24-well plate and recovered by resuspending in 500 μL of DMEM. To assess the viability of EBOV in condoms, 700 μL of semen spiked with 1 × 103 TCID50/mL EBOV was placed in condoms (Durex Extra Sensitive; Reckitt Benckiser Group, Slough, UK) in triplicate, stored at 27°C and 80% RH, and sampled on alternate days. All samples were stored at −80°C until titration. We previously had determined no significant effect on EBOV titers by a single freeze/thaw step (). Titrations were performed on Vero E6 cells in a 48-well format. TCID50 per milliliter was calculated by using the Spearman-Karber method (,). Statistical analysis were performed with GraphPad 6.05 (GraphPad Software, San Diego, CA, USA). Standard curves for EBOV in semen and blood did not significantly differ (analysis of covariance, p = 0.8965) between the slopes of the standard, indicating that the PCR efficiency is similar between the 3 matrices; however, differences in Ct value between semen and blood were significant (analysis of covariance, p<0.0001) (Figure 1, panel A) (). No linear correlation was observed between the Ct value and the dilution factor, together with the additional wash step used during the extraction procedure; this finding suggests that the differences were not due to presence of inhibitors but rather to the efficiency of extraction (Figure 1, panel B). The decrease in extraction efficiency could be related to the nonhomogeneous nature of semen. SE within undiluted samples was larger in semen than in blood (Figure 1, panel B). This finding was confirmed by similar SE variation for the housekeeping gene B2M (semen Ct value 28.34 ± 3.35 and blood Ct value 20.78 ± 0.81). We tested he stability of EBOV in dry and bulk semen for 8 days under tropical conditions (27°C, 80% RH). Under bulk conditions, EBOV was viable for all 8 days at 1 × 106, but at 1 × 103, viable virus was recovered only to day 6. EBOV viability was greatly reduced in dried semen: viable virus was detected to days 4 and 1 at 1 × 106 and 1 × 103, respectively (Figure 2). Viable virus was recovered from semen spiked with 1 × 103 TCID50/mL EBOV stored in condoms to day 6, whereas the Ct value remained stable throughout the experiment. This finding highlights the importance of the proper disposal of condoms used by EVD convalescent men. EBOV RNA was detectable in semen for all 8 days with no decrease in Ct values, suggesting that RNA can be detected in semen samples obtained from convalescent men over an extended time, even if the cold chain is interrupted.
Figure 2

Linear regression model showing stability of Ebola virus (EBOV) and EBOV RNA in semen at 27°C and 80% relative humidity over 8 days. A) EBOV in bulk (liquid) semen versus dry semen at initial titers of 106 TCID50/mL and 103 TCID50/mL. The higher titer 1 × 106 TCID50/mL was used to provide a comparison with EBOV in blood, and the lower titer 1 × 103 TCID50/mL was derived from Ct values reported in semen samples. Viable virus was reduced significantly faster (p<0.0001) in dry semen than in bulk semen. The goodness-of-fit for the linear regression represented as the r2 value is 0.53 for bulk semen and 0.82 for dry semen with an initial titer of 106 TCID50/mL, respectively, and 0.65 for bulk semen with an initial titer of 103 TCID50/mL. No curve is shown for the initial titer 103 TCID50/mL in the dry semen because no viable virus was recovered after day 1. The titer on day 1 was 1.1 log10 TCID50/mL. In all cases except the high-titer bulk semen sample, the final data point was followed by 2 consecutive days of no recovered virus. B) Ct values produced by analysis of bulk semen samples analyzed by real-time quantitative reverse transcription PCR. The data did not fit a linear regression model (r2 = 0.08964), but the RNA clearly remained stable during the entire experiment. Three biologic replicates were analyzed at each time point. Error bars represent mean ± SEM virus titer. Dashed line indicates the limit of detection for the titration assay. An analysis of covariance was used to compare linear regression models and determine differences in virus reduction rates. Ct, cycle threshold; TCID50, 50% tissue culture infectious dose.

Linear regression model showing stability of Ebola virus (EBOV) and EBOV RNA in semen at 27°C and 80% relative humidity over 8 days. A) EBOV in bulk (liquid) semen versus dry semen at initial titers of 106 TCID50/mL and 103 TCID50/mL. The higher titer 1 × 106 TCID50/mL was used to provide a comparison with EBOV in blood, and the lower titer 1 × 103 TCID50/mL was derived from Ct values reported in semen samples. Viable virus was reduced significantly faster (p<0.0001) in dry semen than in bulk semen. The goodness-of-fit for the linear regression represented as the r2 value is 0.53 for bulk semen and 0.82 for dry semen with an initial titer of 106 TCID50/mL, respectively, and 0.65 for bulk semen with an initial titer of 103 TCID50/mL. No curve is shown for the initial titer 103 TCID50/mL in the dry semen because no viable virus was recovered after day 1. The titer on day 1 was 1.1 log10 TCID50/mL. In all cases except the high-titer bulk semen sample, the final data point was followed by 2 consecutive days of no recovered virus. B) Ct values produced by analysis of bulk semen samples analyzed by real-time quantitative reverse transcription PCR. The data did not fit a linear regression model (r2 = 0.08964), but the RNA clearly remained stable during the entire experiment. Three biologic replicates were analyzed at each time point. Error bars represent mean ± SEM virus titer. Dashed line indicates the limit of detection for the titration assay. An analysis of covariance was used to compare linear regression models and determine differences in virus reduction rates. Ct, cycle threshold; TCID50, 50% tissue culture infectious dose. Before the EVD case in the woman reported here, EBOV was known to persist for an extended period in semen (). In November 2014, a man returning to India from Liberia after recovery from EVD produced a positive semen sample while testing negative for EBOV in blood, saliva, and urine by qRT-PCR (,). Isolation of EBOV from semen samples collected during prior outbreaks has been reported. In 1 case, EBOV was isolated from the semen of a convalescent patient 82 days after symptom onset (). EBOV has been detected at 101 days from symptom onset by qRT-PCR (). Sexual transmission has been implicated in Marburg virus infection, but until now only equivocal evidence existed of EBOV transmission through sexual contact (,). Our study has several limitations. First is our use of semen spiked with EBOV rather than naturally infected by EBOV. If EBOV is cell associated in a natural infection, the results of the experiment might be altered, although no difference was observed with blood previously (). Second, the starting titers of EBOV in the semen might not represent naturally occurring levels of viable virus in semen because reported Ct values cannot be inferred toward viable virus or infectiousness. Third, the absolute Ct values presented directly apply to the instruments and reagents used in these experiments. Other systems might yield different Ct values and PCR efficiencies.

Conclusions

Because of the potential for sexual transmission, the World Health Organization and Centers for Disease Control and Prevention have recommended measures to prevent transmission by sexual contact, including semen screening for survivors and use of condoms (,) and safe handling and disposal of condoms (). In a region where organized waste management is almost nonexistent and availability of condoms is limited, to the extent that persons may wash and reuse condoms, this recommendation might not be strictly adhered to. The prolonged viability of EBOV in semen ex vivo supports the WHO recommendation for safe handling and disposal of condoms ().
  10 in total

1.  Ebola virus in the semen of convalescent men.

Authors:  Ian M Mackay; Katherine E Arden
Journal:  Lancet Infect Dis       Date:  2014-11-19       Impact factor: 25.071

2.  India's health ministry inspects airports for Ebola preparedness.

Authors:  Sanjeet Bagcchi
Journal:  BMJ       Date:  2014-11-27

3.  Ethical issues in isolating people treated for Ebola.

Authors:  Mahesh Devnani; Yan Guo
Journal:  BMJ       Date:  2015-01-14

4.  Marburg agent disease: in man.

Authors:  G A Martini
Journal:  Trans R Soc Trop Med Hyg       Date:  1969       Impact factor: 2.184

5.  Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995.

Authors:  L L Rodriguez; A De Roo; Y Guimard; S G Trappier; A Sanchez; D Bressler; A J Williams; A K Rowe; J Bertolli; A S Khan; T G Ksiazek; C J Peters; S T Nichol
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

6.  Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit.

Authors:  A K Rowe; J Bertolli; A S Khan; R Mukunu; J J Muyembe-Tamfum; D Bressler; A J Williams; C J Peters; L Rodriguez; H Feldmann; S T Nichol; P E Rollin; T G Ksiazek
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Assessment of the risk of Ebola virus transmission from bodily fluids and fomites.

Authors:  Daniel G Bausch; Jonathan S Towner; Scott F Dowell; Felix Kaducu; Matthew Lukwiya; Anthony Sanchez; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

8.  Ebola Virus Stability on Surfaces and in Fluids in Simulated Outbreak Environments.

Authors:  Robert Fischer; Seth Judson; Kerri Miazgowicz; Trenton Bushmaker; Joseph Prescott; Vincent J Munster
Journal:  Emerg Infect Dis       Date:  2015-07       Impact factor: 6.883

9.  Possible sexual transmission of Ebola virus - Liberia, 2015.

Authors:  Athalia Christie; Gloria J Davies-Wayne; Thierry Cordier-Lassalle; Thierry Cordier-Lasalle; David J Blackley; A Scott Laney; Desmond E Williams; Shivam A Shinde; Moses Badio; Terrence Lo; Suzanne E Mate; Jason T Ladner; Michael R Wiley; Jeffrey R Kugelman; Gustavo Palacios; Michael R Holbrook; Krisztina B Janosko; Emmie de Wit; Neeltje van Doremalen; Vincent J Munster; James Pettitt; Randal J Schoepp; Leen Verhenne; Iro Evlampidou; Karsor K Kollie; Sonpon B Sieh; Alex Gasasira; Fatorma Bolay; Francis N Kateh; Tolbert G Nyenswah; Kevin M De Cock
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-08       Impact factor: 17.586

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

  10 in total
  12 in total

1.  Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Authors:  John C Kash; Kathie-Anne Walters; Jason Kindrachuk; David Baxter; Kelsey Scherler; Krisztina B Janosko; Rick D Adams; Andrew S Herbert; Rebekah M James; Spencer W Stonier; Matthew J Memoli; John M Dye; Richard T Davey; Daniel S Chertow; Jeffery K Taubenberger
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 2.  The evolution of Ebola virus: Insights from the 2013-2016 epidemic.

Authors:  Edward C Holmes; Gytis Dudas; Andrew Rambaut; Kristian G Andersen
Journal:  Nature       Date:  2016-10-13       Impact factor: 49.962

3.  A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

Authors:  Anita K McElroy; Rama S Akondy; Jessica R Harmon; Ali H Ellebedy; Deborah Cannon; John D Klena; John Sidney; Alessandro Sette; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

4.  Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015.

Authors:  Emmie de Wit; Kyle Rosenke; Robert J Fischer; Andrea Marzi; Joseph Prescott; Trenton Bushmaker; Neeltje van Doremalen; Shannon L Emery; Darryl Falzarano; Friederike Feldmann; Allison Groseth; Thomas Hoenen; Bonventure Juma; Kristin L McNally; Melvin Ochieng; Victor Omballa; Clayton O Onyango; Collins Owuor; Thomas Rowe; David Safronetz; Joshua Self; Brandi N Williamson; Galina Zemtsova; Allen Grolla; Gary Kobinger; Mark Rayfield; Ute Ströher; James E Strong; Sonja M Best; Hideki Ebihara; Kathryn C Zoon; Stuart T Nichol; Tolbert G Nyenswah; Fatorma K Bolay; Moses Massaquoi; Heinz Feldmann; Barry Fields
Journal:  J Infect Dis       Date:  2016-06-21       Impact factor: 5.226

5.  One Health: Addressing Global Challenges at the Nexus of Human, Animal, and Environmental Health.

Authors:  Waithaka Mwangi; Paul de Figueiredo; Michael F Criscitiello
Journal:  PLoS Pathog       Date:  2016-09-15       Impact factor: 6.823

6.  Responding to ever-changing epidemiological dynamics of Ebola virus disease.

Authors:  Yuki Maehira; Yohei Kurosaki; Tomoya Saito; Jiro Yasuda; Masayoshi Tarui; Denis J M Malvy; Tsutomu Takeuchi
Journal:  BMJ Glob Health       Date:  2016-11-24

7.  Analysis of Ebola virus polymerase domains to find strain-specific differences and to gain insight on their pathogenicity.

Authors:  Seema Patel; Snigdha Patel
Journal:  Virusdisease       Date:  2016-07-30

8.  Determining the effect of different environmental conditions on Ebola virus viability in clinically relevant specimens.

Authors:  Bernadett Palyi; Nora Magyar; Judit Henczko; Balint Szalai; Agnes Farkas; Thomas Strecker; Maria Takacs; Zoltan Kis
Journal:  Emerg Microbes Infect       Date:  2018-03-29       Impact factor: 7.163

9.  Comparison of the Aerosol Stability of 2 Strains of Zaire ebolavirus From the 1976 and 2013 Outbreaks.

Authors:  Robert J Fischer; Trenton Bushmaker; Seth Judson; Vincent J Munster
Journal:  J Infect Dis       Date:  2016-08-08       Impact factor: 5.226

10.  Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Authors:  James Logue; Kaylie Tuznik; Dean Follmann; Greg Grandits; Jonathan Marchand; Cavan Reilly; Yeya Dit Sadio Sarro; James Pettitt; Eric J Stavale; Mosoka Fallah; Gene G Olinger; Fatorma K Bolay; Lisa E Hensley
Journal:  J Virol Methods       Date:  2018-02-23       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.